Guizhounli Pharmaceutical Co (SHSE:603439) Payments of Debt: ¥-646 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603439 Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
91 GF Score
Price ¥11.97
GF Value ¥13.31
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Guizhounli Pharmaceutical Co Payments of Debt?

Guizhounli Pharmaceutical Co SHSE:603439 -1.64% 91 Payments of Debt is ¥-646 Mil as of Jun. 2026. GuruFocus rates SHSE:603439 with a GF Score™ of 91/100 and a GF Value™ of ¥13.31 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Guizhounli Pharmaceutical Co's Payments of Debt for the three months ended in Jun. 2026 was ¥-325 Mil.

Guizhounli Pharmaceutical Co's Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was ¥-646 Mil.

Guizhounli Pharmaceutical Co Payments of Debt Related Terms

Guizhounli Pharmaceutical Co Payments of Debt Historical Data

* Premium members only.

The historical data trend for Guizhounli Pharmaceutical Co's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guizhounli Pharmaceutical Co Payments of Debt Chart

Guizhounli Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only -200.00 -200.00 -205.00 -299.85 -418.91

Guizhounli Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -202.43 -74.06 -142.43 -104.21 -324.90
SHSE:603439
91GF Score
Guizhou Sanli Pharmaceutical Co Ltd SHSE:603439
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guizhounli Pharmaceutical Co Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-646 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of ¥-646 Mil mean?
Guizhounli Pharmaceutical Co (SHSE:603439) has a Payments of Debt of ¥-646 Mil as of Jun. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Guizhounli Pharmaceutical Co and its competitors.
Is Guizhounli Pharmaceutical Co's Payments of Debt too high?
Guizhounli Pharmaceutical Co's current Payments of Debt is ¥-646 Mil. Overall, Guizhounli Pharmaceutical Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Guizhounli Pharmaceutical Co's Payments of Debt compare to ZTS?
Guizhounli Pharmaceutical Co's Payments of Debt of ¥-646 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Drug Manufacturers company?
A good Payments of Debt depends on the Drug Manufacturers industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Guizhounli Pharmaceutical Co and its competitors. Guizhounli Pharmaceutical Co's current Payments of Debt is ¥-646 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guizhounli Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co (SHSE:603439) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥13.31, compared to a current price of ¥11.97 — trading 10.1% below its estimated fair value. The current Payments of Debt is ¥-646 Mil. Guizhounli Pharmaceutical Co's overall GF Score™ is 91/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Guizhounli Pharmaceutical Co (SHSE:603439), the current Payments of Debt is ¥-646 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Guizhounli Pharmaceutical Co (SHSE:603439) Overvalued in 2026?

Based on GuruFocus' analysis, Guizhounli Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥11.97 is trading 10.1% below its estimated GF Value™ of ¥13.31. GuruFocus considers Guizhounli Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603439:

  • Payments of Debt: ¥-646 Mil
  • GF Value™: ¥13.31 vs. price of ¥11.97 (10.1% below fair value)
  • GF Score™: 91/100 with 7 warning signs

No single metric tells the full story. See the SHSE:603439 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Guizhounli Pharmaceutical Co Business Description

Address Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
91GF Score

Get the complete analysis for SHSE:603439

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.97
Price
¥13.31
GF Value